10-Q: Goldenwell Biotech Reports Q1 2024 Results: Revenue Declines, Net Loss Persists Amid Going Concern Uncertainty

Goldenwell Biotech's Q1 2024 results reveal a decrease in revenue and a continued net loss, raising concerns about the company's ability to operate as a going concern.

Summary

• Goldenwell Biotech, Inc. reported its financial results for the quarter ended March 31, 2024.
• The company is in the development stage, focusing on R&D, production, and sales of health care and supplement products.
• The financial statements have been prepared on a going concern basis, but the company has sustained an accumulated net loss of $1,258,658 since inception, raising substantial doubt about its ability to continue as a going concern.
• Revenue for the three months ended March 31, 2024, was $158, a significant decrease from $1,422 in the same period of 2023.
• The company recorded a net loss of $30,977 for the quarter ended March 31, 2024, compared to a net loss of $33,606 for the same period in 2023.
• General and administrative expenses were $31,056 for the three months ended March 31, 2024, compared to $34,317 for the three months ended March 31, 2023.
• As of March 31, 2024, the company had a cash balance of $24,221 and a working capital deficit of $121,011.
• The company plans to increase sales of its products and believes it can satisfy its cash requirements through the fiscal year end of December 31, 2023, from its cash of $11,920 as of September 30, 20203.
• The company plans to raise additional funds through debt or equity offerings, but there is no guarantee it will be successful.
• The company estimates it needs approximately $5,000,000 to construct manufacturing facilities and train its workforce, which it estimates would take approximately one year.
• If the company is unable to achieve the financing necessary to continue its plan of operations, then it will not be able to continue the expansion of its business.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with declining revenue, continued losses, and a going concern warning. While there's a slight improvement in net loss compared to the previous year, the overall outlook is negative due to the company's dependence on raising capital and the uncertainty surrounding its ability to do so.

Positives

• The net loss for Q1 2024 was slightly lower than the net loss for Q1 2023 ($30,977 vs $33,606).

Negatives

• Revenue decreased significantly from $1,422 to $158 year-over-year.
• The company has a significant accumulated net loss of $1,258,658 since inception.
• The company has a working capital deficit of $121,011 as of March 31, 2024.
• There is no guarantee that the company will be able to raise additional capital through debt or equity offerings.
• The company's auditors have raised concerns about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on raising capital and achieving profitable operations.
• Failure to secure additional financing could lead to the failure of the business.
• Existing shareholders will experience dilution if the company is successful in completing an equity financing.
• The company faces material hurdles in increasing sales of its products, including constructing manufacturing facilities and training its workforce.
• The company's disclosure controls and procedures were not effective as of March 31, 2024.

Future Outlook

The company plans to increase sales of its products and raise additional funds through debt or equity offerings to fund its business plan and construct manufacturing facilities.

Industry Context

Without specific industry context, it's difficult to provide a detailed analysis. However, early-stage biotech companies often face challenges in generating revenue and securing funding, making Goldenwell's situation not uncommon. The nutraceutical and dietary supplement market is competitive, requiring effective marketing and distribution strategies.

Comparison to Industry Standards

• It is difficult to compare Goldenwell Biotech to industry standards without knowing their specific product focus and target market within the health and supplement industry.
• Many early-stage biotech companies rely heavily on research grants, venture capital, or strategic partnerships for funding, which Goldenwell Biotech does not appear to have secured.
• Compared to established companies like Herbalife or Amway, Goldenwell Biotech's revenue is negligible, and its financial resources are significantly limited.
• Other comparable companies may include smaller, privately held nutraceutical startups, but their financial information is not publicly available.

Legal Proceedings

• The Company is not currently subject to any legal proceedings.

Related Party Transactions

• On June 7, 2021, the Company purchased inventory of $103,125 from Australian Trefoil Heath Technology, which is owned by Li, Yang, the Treasurer of the Company.
• On December 21, 2022, the Company borrowed a long-term loan from Shuang Liu, the Chief Executive Officer of the Company.
• On March 16, 2023, the Company borrowed a long-term loan from Shuang Liu.
• On July 17, 2023, the Company borrowed a long-term loan from Shuang Liu.
• On November 1 and November 14, 2023, the Company borrowed a long-term loan from Shuang Liu.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises capital through equity financing.
• Employees' job security is uncertain due to the company's financial instability.
• The company's ability to meet its obligations to suppliers and creditors is questionable.
• Customers may be affected if the company is unable to continue operations and provide its products.

Next Steps

• The company plans to increase sales of its products.
• The company plans to raise additional funds through debt or equity offerings.
• The company needs to construct manufacturing facilities and train its workforce.

Key Dates

Keywords

financial statements, biotech, going concern, net loss, revenue, capital raise, Goldenwell Biotech, Q1 2024